Discussion on Necessity of Therapeutic Drug Monitoring for Advanced Maternal Aged Multiparous Women after the “Universal Two-Child Policy”
DU Bo-ran1, FENG Xin1*, SHI Xiang-jun2, YIN Cheng-hong1*, TANG Yan3
1. Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China; 2. School of Pharmaceutical Science, Tsinghua University, Beijing 100084, China; 3. Peking Union Medical College Hospital, Beijing 100032, China
Abstract：OBJECTIVE To investigate whether there is necessity for carrying out pharmaceutical care for advanced maternal aged multiparous women as the number of this special population in our country growing greatly under the “universal two-child” policy. METHODS We compared the pregnancy outcomes of the advanced maternal aged multipara with advanced maternal aged primipara and right aged multipara to investigate the characteristics of advanced maternal aged pregnancy outcomes. Through analyzing the importance and urgency of pharmaceutical care for advanced maternal aged multipara, we explored current status and challenges, and analyzed pregnancy drug risk category and pregnancy drug registry. RESULTS =Compared with advanced maternal aged primipara and right aged multipara, pregnancy outcomes and exposure risk are different in advanced maternal aged multipara. Pregnancy drug risk category and pregnancy drug registry are crucial measures in observing study of pharmaceutical care. CONCLUSION It is necessary to carry out pharmaceutical care for advanced maternal aged multipara. Pregnancy drug risk category and pregnancy drug registry can provide basis for designing interventional study of pharmaceutical care.
杜博冉, 冯欣, 史湘君, 阴赪宏, 唐彦. “全面二孩”政策后高龄经产妇用药监护的必要性探讨[J]. 中国药学杂志, 2019, 54(19): 1631-1636.
DU Bo-ran, FENG Xin, SHI Xiang-jun, YIN Cheng-hong, TANG Yan. Discussion on Necessity of Therapeutic Drug Monitoring for Advanced Maternal Aged Multiparous Women after the “Universal Two-Child Policy”. Chinese Pharmaceutical Journal, 2019, 54(19): 1631-1636.
LAOPAIBOON M, LUMBIGANON P, INTARUT N, et al. Advanced maternal age and pregnancy outcomes:a multicountry assessment. BJOG, 2014, 121(suppl 1):49-56.
[2]
MALKIEL A, PNINA M, ALONI H, et al. Primiparity:a traditional intrapartum obstetric risk reconfirmed. Isr Med Assoc J, 2008, 10(7):508-511.
[3]
CHEN S F, ZHANG C, CHEN Y, et al. Analysis of factors influencing safety of department of obstetrics based on “the second child” policy and investigation of countermeasures . J Shanghai Jiaotong Univ(Med Sci)(上海交通大学学报:医学版),2016,36(5):742-746.
[4]
ZHANG X, LIU K B, LIU F J, et al. Preliminary analysis on the change of high risk pregnancy in Beijing′s Policy of "Two Children Alone". Mater Child Health Care Chin(中国妇幼保健), 2015,30(24):4100-4102.
[5]
WEN Z, ZHANG L J. A retrospective clinical analysis on pregnancy complications and outcomes in multiparas before and after the change of policy on family planning . J Clin Exper Med(临床和实验医学杂志), 2016,15(1):69-72.
[6]
NING F Y, LIANG X L, WEI M, et al. Comparison of the clinical characteristics and pregnancy outcome between the senile and right-age multipara. J Xinxiang Med Coll(新乡医学院学报), 2018,35(5):382-384.
[7]
ZHANG L C. Pregnancy outcomes of older multipara, older primipara and non-older multipara. J Clin Med Pract(实用临床医药杂志), 2016(9):197-198.
[8]
ZHU P J. The clinical research on pregnant situation and outcome of elderly multipara. Zhejiang University, 2015.
[9]
LANIER P, JONSON-REID M. Comparing primiparous and multiparous mothers in a nurse home visiting prevention program . Birth, 2014, 41(4):344-352.
[10]
KENNY L C, LAVENDER T, MCNAMEE R, et al. Advanced maternal age and adverse pregnancy outcome:evidence from a large contemporary cohort. PLoS One, 2013, 8(2):e56583.
[11]
FANG M, FENG H. Influences of parity on pregnancy complications and pregnancy outcomes . Chin J Repr Health(中国生育健康杂志), 2016, 27(4):352-354.
[12]
KHALIL A, SYNGELAKI A, MAIZ N, et al. Maternal age and adverse pregnancy outcome:a cohort study. Ultrasound Obstet Gynecol, 2013, 42(6):634-643.
[13]
ZHANG X Q, HUANG C H, ZHANG Q, et al. Fertility intention for the second child under the selective and universal two-child policies: comparisons and implications. Pop Res(人口研究), 2016, 40(01):87-97.
[14]
YUAN X L, LI L M, HE X K. Analysis on hospital delivery situation before and after implementation of comprehensive two-child policy in Guangdong provincial maternal and child health care hospital. Mater Child Health Care Chin(中国妇幼保健), 2018,33(2):241-243.
[15]
LIU Y, XU L, WU L P. The prevention of postpartum hemorrhage in elderly multipara by the carboprost suppositories. Chin Health Stand Man(中国卫生标准管理), 2016,7(11):88-90.
[16]
DU J, LIU Y, FENG M M, et al. Present situation and analysis of domestic obstetrics and gynecology clinical pharmacy work. Chin Me Herald(中国医药导报), 2016,13(35):44-49.
[17]
HUANG L, YU X Y, ZHAO Q, et al. Research on the supporting measures of education,employment,medical treatment in the case of universal two-child policy. J Sci Teach College Uni(高师理科学刊), 2017,37(3):27-32.
[18]
DU B R, FENG X, SHI X J. Publication and effects of FDA′s new rule for pregnant and lactational women. Chin Pharm J(中国药学杂志), 2016,51(12):1049-1054.
[19]
BRIGGS G G, POLIFKA J. Better data needed from pregnancy registries. Birth Defects Res A Clin Mol Teratol, 2009, 85(2):109-111.
[20]
LI X L, FENG X. Analysis of pregnant and lactating women medication in 490 drug instructions. Chin Pharm J(中国药学杂志), 2013,48(21):1886-1888.
[21]
LU C Y, LI Z S, LI X Y, et al. Research progress of diagnosis and treatment of hyperlipidemia during pregnancy. Med Recap(医学综述), 2016,22(16):3179-3182.
[22]
GREENE M F. FDA Drug labeling for pregnancy and lactation drug safety monitoring systems. Semin Perinatol, 2015, 39(7):520-523.
[23]
WILMER E, CHAI S, KROUMPOUZOS G. Drug safety: pregnancy rating classifications and controversies. Clin Dermatol, 2016, 34(3):401-409.
2019, Vol. 54 
